Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

1/14/26 6:17:54 PM ET

$AKTS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AKTS alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GADICKE ANSBERT

(Last)

(First)

(Middle)

C/O MPM BIOIMPACT LLC

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/12/2026		C		1,314,262⁽¹⁾	A	⁽²⁾	1,655,971	I	See Footnote⁽³⁾⁽⁴⁾
Common Stock	01/12/2026		C		5,914,197⁽⁵⁾	A	⁽²⁾	7,570,168	I	See Footnote⁽³⁾⁽⁶⁾
Common Stock	01/12/2026		C		1,577,119⁽⁷⁾	A	⁽²⁾	9,147,287	I	See Footnote⁽³⁾⁽⁸⁾
Common Stock	01/12/2026		P		1,112,777⁽⁹⁾	A	$18	10,260,064	I	See Footnote⁽³⁾⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series Seed Redeemable Convertible Preferred Stock	⁽²⁾	01/12/2026		C			5,000,000	⁽²⁾	⁽²⁾	Common Stock	1,314,262	$0⁽²⁾	0	I	See Footnote⁽¹⁾⁽³⁾
Series A Redeemable Convertible Preferred Stock	⁽²⁾	01/12/2026		C			22,500,000	⁽²⁾	⁽²⁾	Common Stock	5,914,197	$0⁽²⁾	0	I	See Footnote⁽³⁾⁽⁵⁾
Series B Redeemable Convertible Preferred Stock	⁽²⁾	01/12/2026		C			6,000,000	⁽²⁾	⁽²⁾	Common Stock	1,577,119	$0⁽²⁾	0	I	See Footnote⁽³⁾⁽⁷⁾

1. Name and Address of Reporting Person^*

GADICKE ANSBERT

(Last)

(First)

(Middle)

C/O MPM BIOIMPACT LLC

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM ASSET MANAGEMENT LLC

(Last)

(First)

(Middle)

C/O MPM BIOIMPACT LLC

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Oncology Impact Private Investment Fund 2, L.P.

(Last)

(First)

(Middle)

C/O MPM BIOIMPACT LLC

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.

2. Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

3. The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

4. The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.

5. The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.

6. The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.

7. The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

8. The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.

9. The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.

10. The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

Remarks:

This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2018, L.P.

	/s/ Ansbert Gadicke	01/14/2026
	/s/ Ansbert Gadicke, manager of MPM Asset Management LLC	01/14/2026
	/s/ Ansbert Gadicke, managing member of MPM Oncology Investments 2 LLC	01/14/2026
	/s/ Ansbert Gadicke, managing member of MPM Oncology Investments 2 LLC, the general partner of Oncology Impact Private Investment Fund 2, L.P.	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $AKTS alert in real time by email

Date

Price Target

Rating

Analyst

1/4/2024

$2.00 → $1.00

Overweight → Neutral

Piper Sandler

9/6/2023

$9.25 → $1.75

Buy → Neutral

B. Riley Securities

1/24/2023

$9.25

Buy

B. Riley Securities

11/2/2021

$18.00 → $13.00

Outperform

Oppenheimer

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code (Instr. 8)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Common Stock

01/12/2026

1,314,262⁽¹⁾

⁽²⁾

1,655,971

See Footnote⁽³⁾⁽⁴⁾

Common Stock

01/12/2026

5,914,197⁽⁵⁾

⁽²⁾

7,570,168

See Footnote⁽³⁾⁽⁶⁾

Common Stock

01/12/2026

1,577,119⁽⁷⁾

⁽²⁾

9,147,287

See Footnote⁽³⁾⁽⁸⁾

Common Stock

01/12/2026

1,112,777⁽⁹⁾

$18

10,260,064

See Footnote⁽³⁾⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series Seed Redeemable Convertible Preferred Stock

⁽²⁾

01/12/2026

5,000,000

⁽²⁾

Common Stock

1,314,262

$0⁽²⁾

See Footnote⁽¹⁾⁽³⁾

Series A Redeemable Convertible Preferred Stock

⁽²⁾

01/12/2026

22,500,000

⁽²⁾

Common Stock

5,914,197

$0⁽²⁾

See Footnote⁽³⁾⁽⁵⁾

Series B Redeemable Convertible Preferred Stock

⁽²⁾

01/12/2026

6,000,000

⁽²⁾

Common Stock

1,577,119

$0⁽²⁾

See Footnote⁽³⁾⁽⁷⁾

Date

Price Target

Rating

Analyst

1/4/2024

$2.00 → $1.00

Overweight → Neutral

Piper Sandler

9/6/2023

$9.25 → $1.75

Buy → Neutral

B. Riley Securities

1/24/2023

$9.25

Buy

B. Riley Securities

11/2/2021

$18.00 → $13.00

Outperform

Oppenheimer

Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AKTS

Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AKTS

$AKTS
Press Releases

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

$AKTS
SEC Filings

SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

SEC Form S-8 filed by Aktis Oncology Inc.

SEC Form 8-K filed by Aktis Oncology Inc.

$AKTS
Insider Purchases

Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)